<DOC>
	<DOCNO>NCT02930161</DOCNO>
	<brief_summary>The study design assess safety efficacy different dos dose regimen Runihol , tablet , enteric coat , produce `` NTFF '' POLYSAN '' ( Russia ) , prevention liver disease progression patient non-alcoholic fatty liver disease metabolic syndrome .</brief_summary>
	<brief_title>Runihol Nonalcoholic Fatty Liver Disease Metabolic Syndrome</brief_title>
	<detailed_description>The aim study comparative assessment safety efficacy different dos dose regimen Runihol drug tablet , enteric coat , produce `` NTFF '' POLYSAN `` ( Russia ) placebo tablet , enteric coat , produce '' NTFF `` POLYSAN '' ( Russia ) , administer patient non-alcoholic fatty liver disease metabolic syndrome . Design : multicenter , prospective , randomize , double-blind , placebo-controlled comparative study parallel group . The study perform outpatient basis supervision physician-researcher charge screening whole course study drug therapy . The study consist follow period : - Screening - preliminary examination eligible patient ( duration 14 day ) . - The period therapy - use study drug Runihol® , tablet , enteric coat , produce `` NTFF '' POLYSAN `` ( Russian ) placebo tablet , enteric coat , produce '' NTFF `` POLYSAN '' LLC ( Russia ) , 84 day ( 12 week ) . Following screening , patient meet inclusion criterion criterion exclusion randomly assign three study group proportion 1 : 1 : 1 ) : - Group I : treatment Runihol® , 1 tablet 3 time day , placebo tablet , 1 tablet three time day , 84 day ( 12 week ) . - Group II : treatment Runihol® , 2 tablet 2 time day , morning evening , placebo tablet , 2 tablet day , afternoon , 84 day ( 12 week ) . - Group III : patient receive placebo tablet , 2 tablet 3 time day , 84 day ( 12 week ) . Patient assessment carry course 6 visit . Screening : Visit 0 ( -14 day ... Day 1 ) - Screening : preliminary evaluation patient . Period treatment : Visit 1 ( Day 1 ) - evaluation patient base result physical examination , assessment vital sign , complex laboratory ( clinical biochemical blood test , PTI , insulin resistance index calculation , determination homocysteine serum / plasma , general urine analysis ) instrumental ( ECG ) investigation ; randomization , appointment therapy , assessment concomitant therapy , instruction fill patient 's diary , registration AEs . Visit 2 ( Day 15 ) - evaluation patient base result physical examination , assessment vital sign , laboratory complex ( clinical biochemical blood test , PTI , determination homocysteine blood serum , total urine analysis ) instrumental ( ECG ) study ; control intake study medication / placebo , evaluation concomitant therapy , check patient diary , registration AEs . Visit 3 ( Day 29 ) - evaluation patient base result physical examination , assessment vital sign , laboratory complex ( clinical biochemical blood test , PTI , determination homocysteine serum / plasma , total urine analysis ) instrumental ( ECG ) investigation ; control intake study medication / placebo , evaluation concomitant therapy , check patient diary , registration AEs . Visit 4 ( Day 57 ) - evaluation patient base result physical examination , assessment vital sign , laboratory complex ( clinical biochemical blood test , PTI , determination homocysteine serum / plasma , total urine analysis ) instrumental ( ECG ) study ; control intake study medication / placebo , evaluation concomitant therapy , check patient diary , registration AEs . Visit 5 ( Day 85 ) - evaluation patient base result physical examination , assessment vital sign , laboratory complex ( clinical biochemical blood test , PTI , determination homocysteine serum / plasma , insulin resistance index calculation , total urine analysis ) instrumental ( ECG , ultrasound abdomen ) investigation ; control intake study medication / placebo , evaluation concomitant therapy , check patient diary , registration AEs . The study expect include , randomize least 162 patient ( men woman age 18 65 year ) clinically histologically confirm diagnosis non-alcoholic fatty liver disease ( code ICD-10 : K76.0 : Fatty degeneration liver , classify elsewhere ) form non-alcoholic steatohepatitis metabolic syndrome , provide write informed consent participate study , relevant criterion inclusion study criterion exclusion ; data collect used analysis safety efficacy . In view possible dropout patient screen study total 204 patient plan inclusion .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Titanium dioxide</mesh_term>
	<criteria>1 . A sign informed consent participate study . 2 . Men woman age 18 65 year . 3 . Diagnosis : nonalcoholic fatty liver disease ( code ICD10 : K76.0 Fatty degeneration liver , classify elsewhere ) , define nonalcoholic steatohepatitis . 4 . Metabolic syndrome ( accord national criterion accepted 2013 ) . 5 . The body mass index ( BMI ) 3045 kg / m2 . 6 . The presence sign steatosis ultrasound examination liver ( distal signal attenuation / increase echogenicity liver ) . 7 . The level total cholesterol &gt; 6.0 mmol/l / triglyceride level &gt; 1.7 mmol/l . 8 . ALT , AST serum level exceed upper normal limit 1,57 time . 9 . GGT level high upper normal limit 1,57 time . 10 . The level SBP &gt; 140 / DBP &gt; 90 mm Hg antihypertensive therapy require maintain normal blood pressure value . 11 . A negativepregnancy test female participant . 12 . Consent use appropriate method contraception ( contraceptive reliability 90 % : cervical cap spermicide , diaphragm spermicide , condom , intrauterine device ) , abstain sexual activity study period . 13 . Consent limit alcohol consumption maximum 2 unit alcohol per month ( 1 unit alcohol equivalent 0.5 liter beer , 200 ml dry wine 50 ml spirit ) , total abstain alcohol consumption study period . 1 . Chronic liver disease aetiology . 2 . Disorders copper metabolism , and/or ceruloplasmin serum level beyond reference value screen . 3 . Disorders iron metabolism past medical history reveal screening . 4 . Cirrhotic stage nonalcoholic fatty liver disease ( Class AC ChildPugh ) . 5 . Type I diabetes mellitus . 6 . Type II diabetes mellitus , require regular oral hypoglycemic therapy insulin , level fast plasma glucose &gt; 7 mmol / l / glycosylated hemoglobin &gt; 7 % screening . 7 . Any severely decompensated somatic disease 8 . Regular intake medication prohibit study protocol , intake within 4 week prior inclusion . 9 . The history clinically significant allergic reaction . 10 . Hypersensitivity component study drug / intolerance component study drug . 11 . Bariatric surgery le 6 month prior study . 12 . Pregnancy lactation . 13 . Hyperhomocysteinemia ( homocysteine serum level &gt; 15 mmol/dL men , &gt; 12 mmol/dL woman ) . 14 . Exacerbation stomach ulcer / duodenal ulcer / erosive gastritis . 15 . Chronic kidney failure ( stage C4C5 ) / glomerular filtration rate &lt; 30 ml / min screening . 16 . Gout , need drug reduce uric acid level 17 . Any following parameter : Hb &lt; 80 g / L , platelets &lt; 80 x 10 9 / L , WBC &gt; 15 x 10 9 / L screening . 18 . Regular intake 5 unit alcohol per week ( 1 unit alcohol equivalent 0.5 liter beer , 200 ml dry wine 50 ml spirit ) history alcohol addiction . 19 . A significant ( 5 kg ) weight loss weight gain precede 6 month prior study . 20 . Unstable angina pectoris . 21 . Myocardial infarction within 3 month inclusion . 22 . Chronic heart failure ( IIIIV functional class NYHA ) . 23 . A history cancer , mental illness , HIV , tuberculosis , drug addiction . 24 . Mental , physical reason allow patient comply study procedure . 25 . Any condition , accord investigator 's judgement , may interfere compliance study procedure . 26 . Participation clinical trial within 3 month prior inclusion . 27 . Employees research company study site involve conduct present study , family member .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Nonalcoholic Fatty Liver Disease</keyword>
	<keyword>Nonalcoholic Steatohepatitis</keyword>
	<keyword>Methionine</keyword>
	<keyword>Succinic acid</keyword>
</DOC>